GMAB.CO Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 geg. 2024 @ 17:59):

Stats
Dzisiejszy wolumen	93 580.00
Średni wolumen	128 106
Kapitalizacja rynkowa	131.06B
EPS	DKK20.18 ( 2024-05-02 )
Następna data zysków	( DKK22.15 ) 2024-07-31
Last Dividend	DKK0 ( N/A )
Next Dividend	DKK0 ( N/A )
P/E	24.25
ATR14	DKK1.303 (0.06%)

Wolumen Korelacja

Długi: 0.17 (neutral)

Krótki: 0.81 (strong)

Signal:(58.5) Same movement expected

Genmab A/S Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Genmab A/S Korelacja - Waluta/Towar

-0.49
( neutral )

-0.31
( neutral )

-0.01
( neutral )

0.31
( neutral )

-0.23
( neutral )

0.68
( moderate )

Genmab A/S Finanse

Annual	2023
Przychody:	DKK16.47B
Zysk brutto:	DKK16.25B (98.63 %)
EPS:	DKK66.64

FY	2023
Przychody:	DKK16.47B
Zysk brutto:	DKK16.25B (98.63 %)
EPS:	DKK66.64

FY	2022
Przychody:	DKK14.60B
Zysk brutto:	DKK14.60B (100.00 %)
EPS:	DKK83.38

FY	2021
Przychody:	DKK8.48B
Zysk brutto:	DKK0.00 (0.00 %)
EPS:	DKK46.00

Financial Reports:

No articles found.

Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.